Application of the Diabetes Algorithm to a Patient

Size: px
Start display at page:

Download "Application of the Diabetes Algorithm to a Patient"

Transcription

1 Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent real patients and are designed to show how different physicians approach patient management. This information serves as a springboard for discussion, and does not imply AACE s endorsement of any specific treatment approach.

2 Case #3 John John is a 62 year-old African American man, with type 2 diabetes, diagnosed 10 years ago He works as a electrician and has irregular meal times He tries to avoid sweets He smokes 1 pack a day and drinks 1-2 beers a night He is 3 months late on his 6-month checkup He has a history of CAD, depression, and hypertension CAD = coronary artery disease

3 Case #3, John Diabetes Checkup John reports feeling anxious sometimes for no clear reason; at these times, his hands become clammy and tremble and he becomes sweaty Height: 6 2, Weight: 234 lbs, BMI: 30 kg/m 2 BP 184/100 mm Hg, HR 90 bpm ROS negative except poor glucose control BMI = body mass Index; BP = blood pressure; HR = heart rate; lb = pounds; ROS = review of systems

4 A1C = glycated hemoglobin; ASA = aspirin; BID = twice daily; BMI = body mass Index; BP = blood pressure; CGM = continuous glucose monitoring; egrf = estimated glomerular Current labs: - A1C: 9.4%; Case #3, John Diabetes Checkup - Home blood glucose ranges: FPG mg/dl; premeal mg/dl Serum creatinine: 2.3 mg/dl, LFTs normal, urine albumin: 92 mg/g creatinine, TC 153 mg/dl, LDL 70 mg/dl, HDL 41 mg/dl, TG 225 mg/dl egfr 44 ml/min Current medications: Metformin, 1000 mg BID Glimepiride, 4 mg QD Sitagliptin, 100 mg QD ASA, 81 mg QD Benazepril, 40 mg QD Simvastatin, 40 mg QD Escitalopram, 10 mg QD

5 What do John s symptoms of anxiety, trembling, sweating, and clammy hands suggest? (a) (b) (c) (d) Hyperglycemia Hypoglycemia Hypothyroidism GERD? GERD = gastroesophageal reflux disease

6 H.Rettinger, M.D. Symptoms of Hypoglycemia Are Like Falling in Love for the First You get nervous and jittery You get hot and sweaty Time! Your heart starts beating rapidly And last you want to say something intelligent, but only gibberish comes out!

7 John s Self-monitoring Blood Glucose Download Frequent episodes of hypoglycemia due to sulfonylurea and chronic kidney disease

8 What would you do next to adjust John s treatment? (a) (b) (c) (d) Stop metformin and add basal insulin Stop glimepiride and add basal insulin Only continue sitagliptin and add basal insulin Stop all oral medications and start basal/bolus insulin?

9 Road Map To Achieve Glycemic Goals: John s A1C = 9.4% AGI = alpha glucosidase inhibitor; BG = blood glucose; DPP-4 = dipeptidyl peptidase 4; FBG = fasting blood glucose; GLP = glucagon-like peptide-1; MET = metformin; NAFLD = John is already on triple therapy with A1C still >9%; likely having hypoglycemia He may continue sitagliptin, as this will decrease potential need for bolus insulin and reduce post-prandial glycemic variability; however, due to his increased Cr, his sitagliptin dose should be reduced to 50 mg Basal insulin should be initiated Hypoglycemia was driven by the SU and that is why it was stopped Garber AJ, et al. Endocr Pract. 2017, doi: /ep cs.

10 How will you manage John s current BP? John s current BP is 182/100 mm Hg, pulse 90: how will you approach management of his BP? (a) Counsel on diet and lifestyle changes (b) Start John on a beta-blocker, carvedilol 6.25 mg BID (given known CAD, rapid pulse) and schedule a follow up visit in 1 week (c) Recommend reductions in his alcohol consumption (d) Recommend a smoking cessation program (e) All of the above? BID = twice daily; BP = blood pressure; CAD = coronary artery disease; mg = milligram; mm Hg = millimeter of mercury

11 John starts with basal analog insulin 10 units at bedtime John gave himself the first injection in the office, using an insulin pen He was provided with a self-titration schedule He was prescribed carvedilol 6.25 mg BID (does not increase blood glucose) He was counseled to perform SMBG fasting and at bedtime He was taken off glimepiride He was taken off SU BID = twice daily; BP = blood pressure; mg = milligrams; SMBG = self-monitored blood glucose.

12 John BP Check-up Visit At 1-week follow up, John s BP is 156/92 mm Hg His carvedilol dose is increased to 12.5 mg BID His wife is very supportive in helping him make dietary changes He is referred to a dietitian for help with specific food questions He is doing well with insulin pen injections, and has been following his self-titration schedule BID = twice daily; BP = blood pressure; mg = milligram; mm Hg = millimeters of mercury.

13 John 3-month Checkup Height: 6 2, Weight: 228 lbs, BMI: 29 kg/m 2 BP 130/84 mm Hg, HR 68 bpm Foot and fundoscopy exam: no change since prior visit Labs: A1C: 7.9% Serum creatinine: 2.3 mg/dl Urine albumin : 60 mg/g, LFTs normal Current medications: Sitagliptin, 50 mg QD ASA, 81 mg 50 U/d long-acting insulin analog Benazepril, 40 mg QD Simvastatin, 40 mg QD Escitalopram, 10 mg QD Carvedilol, 12.5 mg BID A1C = glycated hemoglobin A1C; ASA = Aspirin; BID = twice daily; BMI = body mass Index; BP = blood pressure; dl = deciliter; FBG = fasting blood glucose; g = gram; HDL = high density lipoproteins; HR = heart rate; lb = pounds; kg = kilogram; LDL = Low density liproproteins; LFT = liver function test; m 2 = meters square; mg = milligram; ROS = review of systems; SMBG = self blood glucose monitoring; SQ = Subcutaneous; TC = total cholesterol; TG = triglycerides; WNL = within normal limits; QD = once daily; hs = before bed.

14 John SMBG Log John brought in examples of his SMBG log Time BG (mg/dl) Time BG (mg/dl) Time BG (mg/dl) 8:00 (fasting) 126 7:30 (fasting) 134 8:00 (fasting) 136 1:00 (post-lunch) Missed reading 1:00 (post-lunch) 214 1:00 (post-lunch) 229 5:30 (post-dinner) 210 6:30 (post-dinner) Missed reading 5:30 (post-dinner) 240 9:30 (bedtime) :00 (bedtime) 219 9:30 (bedtime) 197 BG= blood glucose; dl = deciliter; mg = milligram; SMBG=self-monitoring of blood glucose

15 John What is the best option? (a) Increase his basal insulin dose (b) Add a rapid-acting insulin with each meal (c) Add rapid acting analog to his largest meal (d) Switch to premix insulin?

16 Options When Not at Goal with One Injection of Basal Insulin Basal Plus Add prandial insulin at main meal or Switch to Basal/Bolus or Switch to a premixed insulin analog Divide dose in half and give twice daily (breakfast and dinner) after meals if feeding uncertain

17 John Basal Plus Bolus Mealtime Insulin Use rapid-acting analogs, not regular insulin Easier timing, less postprandial hypoglycemia Can be taken up to 15 minutes after starting to eat May start with 1 injection, at largest meal; however most patients need a dose with each meal 4 units and titrate OR by weight U/kg OR 1 U/15 gms CHO and titrate Titrate to: <140 mg/dl 2 hours post-prandial OR <110 mg/dl next meal or bedtime Stop oral SUs/glinides when prandial insulin is started CHO = carbohydrates; dl = deciliter; kg = kilogram; mg = milligram, SU = sulfonylurea; U = unit.

18 John 3-month Follow-up Height: 6 2, Weight: 210 lbs, BMI: 27 kg/m 2, BP: 130/78 mm Hg, HR: 80 bpm Foot exam: no change since prior visit Labs: A1C: 6.4%; FPG: mg/dl; 2-h PPG: mg/dl Serum creatinine: 2.1 mg/dl Urine albumin: 20 mg/g, LFTs normal Current medications: 50 U long-acting analog insulin SQ hs 12 U rapid-acting insulin SQ with breakfast and lunch 15 U rapid-acting insulin SQ with dinner John will follow up in 3 months Benazepril 40 mg QD Simvastatin 40 mg QD Escitalopram 10 mg QD Carvedilol 12.5 mg BID ASA 81 mg QD ASA = Aspirin; A1C = glycated hemoglobin A1C; BID = twice daily; BMI = body mass Index; BP = blood pressure; dl = deciliter; FBG = fasting blood glucose; HDL = high density lipoproteins; g= gram; HR = heart rate; kg = kilogram; m 2 = meter squared; lb = pounds; LDL = low density lipoproteins; LFT = liver function test; mg = milligram; PPG = postprandial glucose; ROS = review of systems; SMBG = self-monitoring of blood glucose; SQ = subcutaneous; TC = total cholesterol; TG = triglycerides; U = units; WNL = within

19 And Finally: The 5 Keys of Successful Diabetes Self-management 1. Know your metabolic targets (A1C, lipids, blood pressure) 2. Understand how to achieve your metabolic targets 3. Stop smoking 4. Take your medicines 5. Make sure your doctor/provider understands the complexities of diabetes management Unger J. Diabetes Management in Primary Care, 2 nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2012.

Application of the Diabetes Algorithm to Patients

Application of the Diabetes Algorithm to Patients Application of the Diabetes Algorithm to Patients Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent

More information

Application of the Diabetes Algorithm to a Patient

Application of the Diabetes Algorithm to a Patient Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent

More information

A Practical Approach to the Use of Diabetes Medications

A Practical Approach to the Use of Diabetes Medications A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE

More information

Complete this CE activity online at ProCE.com/InsulinPart2

Complete this CE activity online at ProCE.com/InsulinPart2 Complete this CE activity online at ProCE.com/InsulinPart2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over

More information

Type 2 Diabetes Mellitus Insulin Therapy 2012

Type 2 Diabetes Mellitus Insulin Therapy 2012 Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration

More information

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell

More information

UKPDS: Over Time, Need for Exogenous Insulin Increases

UKPDS: Over Time, Need for Exogenous Insulin Increases UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin

More information

Update on Insulin-based Agents for T2D

Update on Insulin-based Agents for T2D Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment

More information

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Timely!Insulinization In!Type!2! Diabetes,!When!and!How Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for

More information

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female

More information

Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE

Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer

More information

The Many Faces of T2DM in Long-term Care Facilities

The Many Faces of T2DM in Long-term Care Facilities The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment

More information

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning

More information

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide

More information

Your Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine

Your Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Your Chart Review Data Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Participation 243 registered for the program 98 have completed the Practice

More information

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better

More information

Insulin Intensification: A Patient-Centered Approach

Insulin Intensification: A Patient-Centered Approach MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director

More information

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES Risk Factors or Complications Glycemic Control Fasting & Capillary Plasma Glucose Anti-platelet

More information

RCHC Clinical Guidelines Type 2 Diabetes; Adults

RCHC Clinical Guidelines Type 2 Diabetes; Adults RCHC Clinical Guidelines Type 2 Diabetes; Adults Screening for diabetes in asymptomatic adults 1 Population: Aged > 45 years; Aged < 45 years who are overweight (BMI> 25kg/m 2 ) and have an additional

More information

Type 2 Diabetes Performance Improvement Initiative: Chart Reviews. Lara Zisblatt Boston University School of Medicine Boston, MA

Type 2 Diabetes Performance Improvement Initiative: Chart Reviews. Lara Zisblatt Boston University School of Medicine Boston, MA Type 2 Diabetes Performance Improvement Initiative: Chart Reviews Lara Zisblatt Boston University School of Medicine Boston, MA Participants in the Program 487 people registered 217 people started the

More information

Participants in the Program

Participants in the Program Type 2 Diabetes Performance Improvement Initiative: Chart Reviews Lara Zisblatt Boston University School of Medicine Boston, MA Participants in the Program 487 people registered 217 people started the

More information

Diabetes Overview. How Food is Digested

Diabetes Overview. How Food is Digested Diabetes Overview You are The Teacher, The Coach and the Fan Pathophysiology of Diabetes Complications Know the Numbers Treatment Can Good Control Make a Difference? Can Tight Control Be too Tight? How

More information

Insulin Initiation, titration & Insulin switch in the Primary Care-KISS

Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda

More information

Comprehensive Diabetes Treatment

Comprehensive Diabetes Treatment Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes

More information

Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes

Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations

More information

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool Self-Monitoring Blood Glucose () Pattern Recommendation: Basal Insulin Only (To Target) NPH or long-acting analogue, typically given at. at least as often as is being given. Optional, less frequent can

More information

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral

More information

Multiple Factors Should Be Considered When Setting a Glycemic Goal

Multiple Factors Should Be Considered When Setting a Glycemic Goal Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital

INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia

More information

Glycemic Control IU Health Diabetes Centers

Glycemic Control IU Health Diabetes Centers Glycemic Control IU Health Diabetes Centers Central Nursing Orientation 3/10/2014 1 Objectives Identify laboratory results that diagnosis diabetes and reflect glycemic control Describe glycemic control

More information

Adult Diabetes Clinician Guide NOVEMBER 2017

Adult Diabetes Clinician Guide NOVEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.

More information

ABFM Diabetes SAM Part 4

ABFM Diabetes SAM Part 4 ABFM Diabetes SAM Part 4 37. A 55-year-old male with type 2 diabetes mellitus has a chronic history of reduced libido and erectile dysfunction. On examination you note hepatomegaly and mild testicular

More information

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott

More information

Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes

Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical

More information

Using Insulin in the Primary Care Setting: Interactive Cases

Using Insulin in the Primary Care Setting: Interactive Cases Using Insulin in the Primary Care Setting: Interactive Cases Irl B. Hirsch, MD University of Washington School of Medicine Dualities (Nov, 2011) Research Grants: sanofi-aventis, Novo Nordisk, Halozyme,

More information

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes

More information

Insulin Initiation and Intensification. Disclosure. Objectives

Insulin Initiation and Intensification. Disclosure. Objectives Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School

More information

APPENDIX American Diabetes Association. Published online at

APPENDIX American Diabetes Association. Published online at APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no

More information

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they

More information

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD STUDY SYNOPSIS Study number Title HMR1964A/3502 Apidra (insulin glulisine) administered in a fixed-bolus regimen vs. variable-bolus regimen based on carbohydrate counting in adult subjects with type 2

More information

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,

More information

LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA

LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA Anne Leake, PhD, APRN-Rx, BC-ADM ECHO Diabetes Learning Group 3/28/2018 Objectives 1. Identify common preventable causes of hypoglycemia

More information

Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease

Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Authored by Paul Zimmet and Richard Nesto on behalf of the Global Partnership for Effective Diabetes Management.

More information

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Clinical Cases in Diabetes Management. Joseph Cook D.O. Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient

More information

Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD

Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD International Diabetes Center and Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com

More information

Individualizing Therapy int2dm With Insulin

Individualizing Therapy int2dm With Insulin Individualizing Therapy int2dm With Insulin Etie Moghissi, MD, FACP, FACE Clinical Associate Professor University of California, Los Angeles Los Angeles, California OBJECTIVES: At the conclusion of this

More information

Have participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call, , mail).

Have participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call,  , mail). Blood Pressure Management and Control Protocol BP Management: A) BP goal: Achieve blood pressure values less than 130/80mmHg. B) Process: Have participants measure their blood pressure daily at a standard

More information

Current Clinical Practice Guideline for Diabetes Management

Current Clinical Practice Guideline for Diabetes Management Current Clinical Practice Guideline for Diabetes Management Chaicharn Deerochanawong M.D. Professor of Medicine, i Rangsit Medical University it Diabetes and Endocrinology Unit Department of Medicine Rajavithi

More information

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.

More information

CURRENT CONTROVERSIES IN DIABETES CARE

CURRENT CONTROVERSIES IN DIABETES CARE CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact

More information

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:

More information

Treat-to-Target Tools

Treat-to-Target Tools TEAMcare Care Manager Primary Care Provider Treat to Target Discussion Tool for Treatment Enhancement Activation and Motivation (TEAM) Depression, Diabetes and Coronary Heart Disease (CHD) Intervention

More information

Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus

Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

DEMYSTIFYING INSULIN THERAPY

DEMYSTIFYING INSULIN THERAPY DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING

More information

Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes

Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009

More information

It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia

It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia Jacqueline LaManna, PhD, ANP BC, BC ADM, CDE Holly Divine, PharmD, BCACP, CGP, CDE, FAPhA Disclosures Dr. Jacqueline LaManna

More information

Type 2 Diabetes Mellitus 2011

Type 2 Diabetes Mellitus 2011 2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose

More information

Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes

Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes Taking It to the Next Level: Pearls for Your Clinical Practice Thursday, April 23, 2009 6:00 AM - 8:00

More information

AACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM

AACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM AACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013 TASK FORCE Alan J. Garber, MD, PhD, FACE, Chair Martin J. Abrahamson, MD Joshua I. Barzilay, MD, FACE Lawrence Blonde, MD, FACP, FACE Zachary T. Bloomgarden,

More information

Insulin and Post Prandial

Insulin and Post Prandial Insulin and Post Prandial Pr Luc Martinez PCDE Meeting Barcelona 2016 Conflicts of interest disclosure Advis consultant f Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Lilly; Mayoly

More information

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010 Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number

More information

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients

More information

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million

More information

5/16/2018. Insulin Workshop. Disclosures to Participants. Learning Objectives. This presentation will cover the following learning objectives:

5/16/2018. Insulin Workshop. Disclosures to Participants. Learning Objectives. This presentation will cover the following learning objectives: Insulin Workshop Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Holly Divine, PharmD, BCACP, BCGP, CDE,

More information

Diabetes Self-Management Education Record

Diabetes Self-Management Education Record Diabetes Self-Management Education Record Patient Label Record level of competence and Initial: O=outcomes met; RT=reinforce teaching; NA=not applicable; P=prior knowledge Clinical Outcomes Information

More information

Personal Diabetes Passport

Personal Diabetes Passport Personal Diabetes Passport Contact information: Name: Physician: Diabetes Education Centre: Dietitian: Ophthalmologist: Chiropodist: Type of Diabetes: Type 1 (T1DM) Increased risk for diabetes Type 2(T2DM)

More information

Common Diabetes-related Terms

Common Diabetes-related Terms Common Diabetes-related Terms A1C An A1C test measures a person's average blood glucose level over two to three months. Hemoglobin is the part of a red blood cell that carries oxygen to the cells and sometimes

More information

CURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013

CURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013 CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI

More information

Analyzing Glucose Data

Analyzing Glucose Data Analyzing Glucose Data Objectives Identify when insulin needs to be adjusted Identify pattern of high and low BGs Provide sources of information on how to adjust insulin Titrate insulin doses based on

More information

More Than Just the Numbers:

More Than Just the Numbers: More Than Just the Numbers: Individualising Patient Care ADEA-QLD Branch Conference 20 April 2018 Case Study 1 Child with Type 1 Diabetes 2 Background and Social History 10 year old female with T1DM since

More information

American Diabetes Association 2018 Guidelines Important Notable Points

American Diabetes Association 2018 Guidelines Important Notable Points American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating

More information

4/10/2015. Foundations to Managing Inpatient Hyperglycemia. Learning Objectives

4/10/2015. Foundations to Managing Inpatient Hyperglycemia. Learning Objectives Foundations to Managing Inpatient Hyperglycemia Module A 1 Learning Objectives Develop strategies to identify patients with hyperglycemia or diabetes in the inpatient setting Establish glycemic goals to

More information

Addressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker:

Addressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker: Addressing Challenges in Type 2 Diabetes Geneva Briggs, PharmD,, BCPS Addressing Challenges in Type 2 Diabetes Speaker: Dr. Geneva Clark Briggs, a board-certified Pharmacotherapy Specialist, received her

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Learning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications

Learning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications Treatment Strategies to Maximize the Value of Diabetes Medications Presenters: Jennifer Toy, PharmD, BCACP and Crystal Zhou, PharmD, APh AHSCP, BCACP Learning Objectives 1. Discuss which patients may benefit

More information

Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D

Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with

More information

Efficacy/pharmacodynamics: 85 Safety: 89

Efficacy/pharmacodynamics: 85 Safety: 89 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:

More information

PHYSICIANS INTERACTIVE PARTICIPANT GUIDE

PHYSICIANS INTERACTIVE PARTICIPANT GUIDE PHYSICIANS INTERACTIVE PARTICIPANT GUIDE Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages

More information

Case Study. Patient Profile. Baseline Report - Daily Patterns. Insights

Case Study. Patient Profile. Baseline Report - Daily Patterns. Insights Case Study Patient Profile Sex/Age: Female, 48 years old Disease diagnosis: Type 2 for past 13 years, coronary artery disease for 3 years, complains of severe tiredness HbA1c: 9.0% Diabetes medication

More information

DM in OPD for Internist. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 28 Oct 2013

DM in OPD for Internist. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 28 Oct 2013 DM in OPD for Internist Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 28 Oct 2013 Outlines DM management GDM Case Somjit is a 43-year-old woman Check-up No abnormal symptom Laboratory FBS

More information

TEAMcare Treat-to-Target Tools

TEAMcare Treat-to-Target Tools TEAMcare Treat-to-Target Tools The TEAMcare Treatment Discussion Tool (treatment protocol) Nurse Case Manager (NCM)-MD Treat-to-Target Discussion Tool for Treatment Enhancement Activation and Motivation

More information

Diabetes Mellitus Type 2

Diabetes Mellitus Type 2 Diabetes Mellitus Type 2 What is it? Diabetes is a common health problem in the U.S. and the world. In diabetes, the body does not use the food it digests well. It is hard for the body to use carbohydrates

More information

2/4/13. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing

2/4/13. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing Step 1: Determine etween Intensive Insulin Therapy or Conventional Insulin Therapy Intensive Insulin Therapy (IIT) y definition, IIT attempts to mimic the body s normal release of insulin and therefore,

More information

Chief of Endocrinology East Orange General Hospital

Chief of Endocrinology East Orange General Hospital Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage

More information

Diabetes Mellitus in Older Adults. Presenter Disclosure Information

Diabetes Mellitus in Older Adults. Presenter Disclosure Information Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from

More information

9/28/2012. Sponsored By: NDSU College of Pharmacy, Nursing and Allied Sciences

9/28/2012. Sponsored By: NDSU College of Pharmacy, Nursing and Allied Sciences Sponsored By: NDSU College of Pharmacy, Nursing and Allied Sciences By PresenterMedia.com Faculty: Wendy Brown Pharm.D, PA-C, AE-C Associate Professor Pharmacy Practice About the Patient Clinical Coordinator

More information

The importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R

The importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R Diabetes Management The importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R Connie A Valdez* 1,2, Leah Fitzgerald 1,2 & Sarah Ziherl Hormachea 2 ABSTRACT

More information

Reason for referral: provide patient education on management of hypoglycemia and glucose monitor

Reason for referral: provide patient education on management of hypoglycemia and glucose monitor Meet Robin Sawyer (otherwise known as PT 1): Let s Create a Care Plan! Reason for referral: provide patient education on management of hypoglycemia and glucose monitor History of present illness: 40 45

More information

Clinical Practice Guidelines

Clinical Practice Guidelines Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework

More information

Progressive Loss of β-cell Function in T2DM

Progressive Loss of β-cell Function in T2DM Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of

More information

Clinical Practice Guideline Key Points

Clinical Practice Guideline Key Points Clinical Practice Guideline Key Points Clinical Practice Guideline 2008 Key Points Diabetes Mellitus Provided by: Highmark Endocrinology Clinical Quality Improvement Committee In accordance with Highmark

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized

More information

Vipul Lakhani, MD Oregon Medical Group Endocrinology

Vipul Lakhani, MD Oregon Medical Group Endocrinology Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment

More information